Objective: To explore the profile of adverse events associated with interferon therapy. Design: Systematic review. Data sources: Electronic and paper records in subject area from 2000 to 2014. Methods: We searched for the studies on safety and tolerability containing adverse events of interferons with systemic effect. Results: The most frequent adverse events were: flu-like syndrome (55%), depression (30%), neutropenia (20%), anemia (13%). Conclusion: Adverse events are a very serious problem of interferon treatment. System of pharmacovigilance provides forecasting and early identification of these adverse events, as they are predictable.

The safety of application of different groups of antibacterial drugs in pediatrics among children is discussed in this article. The analysis was made of spontaneous reports in the national database for 2012, containing information about serious adverse reactions (AR) on antibiotics in the pediatric population. In addition to evaluating the overall structure of serious AR and their distribution to system organ classes, the role of different pharmaco-therapeutic groups of antibacterial drugs in the development of adverse effects of pharmacotherapy was analyzed. Particular attention was drawn to «off-label» prescriptions; their frequency and structures. It was shown that antibiotics are common cause of serious AR among children, and their use as «off-label» prescribed drugs is an additional risk factor for such reactions.

The problems of safety evaluation of medicinal plants formulations in the Russian Federation, Europe and USA are presented. Safety issues of medicinal plants, as well as the adverse reactions of some herbal medicines are discussed. The main groups of exogenous (toxic metals, pesticides) and endogenous toxic substances of medicinal plants are represented. The maximum allowable concentrations of endogenous toxic substances (pyrrolizidine alkaloids, glycolic acid, azaron and other) most often defined in medicinal plants are given. The authors substantiate the necessity of tightening of the requirements for normative documents, which ensure the safety of medicinal plants.

This article provides a retrospective analysis of a case of adverse drug reactions to the drug haloperidol - neuroleptic malignant syndrome. A literature review on the issue of neuroleptic malignant syndrome was represented. The factors that led to this syndrome development of a particular patient were evaluated. Detailed clinical and pharmacological value of gene polymorphism CYP 2D6 is discussed. The data on the successful use of a therapy of neuroleptic malignant syndrome with ethylmethylhydroxypyridine malat are presented.

Two groups of children on therapy with monofluoroquinolones were enrolled in this open research trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim of the study was to compare tolerability (with the focus on arthrotoxicity) of ciprofloxacin, ofloxacin and pefloxacin during intermittent (15-50 mg/kg/day in cystic fibrosis patients) and prolonged continuous therapy (10-15 mg/kg/day in patients with aplastic anemia). Quinolone-induced arthropathy was reported in 7, 6% of all cases, mainly during pefloxacin therapy (31, 8%), and more frequently in patients with aplastic anemia (10, 9% vs. 7, 7%), only in pubertal children, and was fully reversible with no influens on the lineal growth. Following the monofluoroquinolones use, residual joint-related symptoms were not observed because monofluoroquinolones did not achieve chondrotoxic concentrations in cartilaginous structures.